TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia

Marka Van Blitterswijk, Bianca Mullen, Alexandra M. Nicholson, Kevin F. Bieniek, Michael G. Heckman, Matthew C. Baker, Mariely Dejesus-Hernandez, Nicole A. Finch, Patricia H. Brown, Melissa E. Murray, Ging Yuek R Hsiung, Heather Stewart, Anna M. Karydas, Elizabeth Finger, Andrew Kertesz, Eileen H. Bigio, Sandra Weintraub, Marsel Mesulam, Kimmo J. Hatanpaa, Charles L. White & 19 others Michael J. Strong, Thomas G. Beach, Zbigniew K. Wszolek, Carol Lippa, Richard Caselli, Leonard Petrucelli, Keith A. Josephs, Joseph E. Parisi, David S. Knopman, Ronald C. Petersen, Ian R. Mackenzie, William W. Seeley, Lea T. Grinberg, Bruce L. Miller, Kevin B. Boylan, Neill R. Graff-Radford, Bradley F. Boeve, Dennis W. Dickson, Rosa Rademakers

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Variants in transmembrane protein 106 B (TMEM106B) modify the disease penetrance of frontotemporal dementia (FTD) in carriers of progranulin (GRN) mutations. We investigated whether TMEM106B is also a genetic modifier of disease in carriers of chromosome 9 open reading frame 72 (C9ORF72) expansions. We assessed the genotype of 325 C9ORF72 expansion carriers (cohort 1), 586 FTD patients lacking C9ORF72 expansions [with or without motor neuron disease (MND); cohort 2], and a total of 1,302 controls for TMEM106B variants (rs3173615 and rs1990622) using MassArray iPLEX and Taqman genotyping assays. For our primary analysis, we focused on functional variant rs3173615, and employed a recessive genotypic model. In cohort 1, patients with C9ORF72 expansions showed a significantly reduced frequency of carriers homozygous for the minor allele as compared to controls [11.9 vs. 19.1 %, odds ratio (OR) 0.57, p = 0.014; same direction as carriers of GRN mutations]. The strongest evidence was provided by FTD patients (OR 0.33, p = 0.009) followed by FTD/MND patients (OR 0.38, p = 0.017), whereas no significant difference was observed in MND patients (OR 0.85, p = 0.55). In cohort 2, the frequency of carriers homozygous for the minor allele was not significantly reduced in patients as compared to controls (OR 0.77, p = 0.079); however, a significant reduction was observed when focusing on those patients with frontotemporal lobar degeneration and TAR DNA-binding protein 43 inclusions (FTLD-TDP; OR 0.26, p < 0.001). Our study identifies TMEM106B as the first genetic factor modifying disease presentation in C9ORF72 expansion carriers. Homozygosity for the minor allele protects carriers from developing FTD, but not from developing MND; similar effects are seen in FTLD-TDP patients with yet unknown genetic causes. These new findings show that the protective effects of TMEM106B are not confined to carriers of GRN mutations and might be relevant for prognostic testing, and as a promising therapeutic target for the entire spectrum of FTLD-TDP.

Original languageEnglish (US)
Pages (from-to)397-406
Number of pages10
JournalActa Neuropathologica
Volume127
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Frontotemporal Dementia
Chromosomes, Human, Pair 9
Open Reading Frames
Motor Neuron Disease
Odds Ratio
Alleles
Mutation
Frontotemporal Lobar Degeneration
Inborn Genetic Diseases
IgA receptor
Penetrance
DNA-Binding Proteins
Genotype

Keywords

  • Amyotrophic lateral sclerosis
  • C9ORF72
  • Disease modifier
  • Frontotemporal dementia
  • Motor neuron disease
  • TMEM106B

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Cellular and Molecular Neuroscience

Cite this

Van Blitterswijk, M., Mullen, B., Nicholson, A. M., Bieniek, K. F., Heckman, M. G., Baker, M. C., ... Rademakers, R. (2014). TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathologica, 127(3), 397-406. https://doi.org/10.1007/s00401-013-1240-4

TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. / Van Blitterswijk, Marka; Mullen, Bianca; Nicholson, Alexandra M.; Bieniek, Kevin F.; Heckman, Michael G.; Baker, Matthew C.; Dejesus-Hernandez, Mariely; Finch, Nicole A.; Brown, Patricia H.; Murray, Melissa E.; Hsiung, Ging Yuek R; Stewart, Heather; Karydas, Anna M.; Finger, Elizabeth; Kertesz, Andrew; Bigio, Eileen H.; Weintraub, Sandra; Mesulam, Marsel; Hatanpaa, Kimmo J.; White, Charles L.; Strong, Michael J.; Beach, Thomas G.; Wszolek, Zbigniew K.; Lippa, Carol; Caselli, Richard; Petrucelli, Leonard; Josephs, Keith A.; Parisi, Joseph E.; Knopman, David S.; Petersen, Ronald C.; Mackenzie, Ian R.; Seeley, William W.; Grinberg, Lea T.; Miller, Bruce L.; Boylan, Kevin B.; Graff-Radford, Neill R.; Boeve, Bradley F.; Dickson, Dennis W.; Rademakers, Rosa.

In: Acta Neuropathologica, Vol. 127, No. 3, 03.2014, p. 397-406.

Research output: Contribution to journalArticle

Van Blitterswijk, M, Mullen, B, Nicholson, AM, Bieniek, KF, Heckman, MG, Baker, MC, Dejesus-Hernandez, M, Finch, NA, Brown, PH, Murray, ME, Hsiung, GYR, Stewart, H, Karydas, AM, Finger, E, Kertesz, A, Bigio, EH, Weintraub, S, Mesulam, M, Hatanpaa, KJ, White, CL, Strong, MJ, Beach, TG, Wszolek, ZK, Lippa, C, Caselli, R, Petrucelli, L, Josephs, KA, Parisi, JE, Knopman, DS, Petersen, RC, Mackenzie, IR, Seeley, WW, Grinberg, LT, Miller, BL, Boylan, KB, Graff-Radford, NR, Boeve, BF, Dickson, DW & Rademakers, R 2014, 'TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia', Acta Neuropathologica, vol. 127, no. 3, pp. 397-406. https://doi.org/10.1007/s00401-013-1240-4
Van Blitterswijk M, Mullen B, Nicholson AM, Bieniek KF, Heckman MG, Baker MC et al. TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathologica. 2014 Mar;127(3):397-406. https://doi.org/10.1007/s00401-013-1240-4
Van Blitterswijk, Marka ; Mullen, Bianca ; Nicholson, Alexandra M. ; Bieniek, Kevin F. ; Heckman, Michael G. ; Baker, Matthew C. ; Dejesus-Hernandez, Mariely ; Finch, Nicole A. ; Brown, Patricia H. ; Murray, Melissa E. ; Hsiung, Ging Yuek R ; Stewart, Heather ; Karydas, Anna M. ; Finger, Elizabeth ; Kertesz, Andrew ; Bigio, Eileen H. ; Weintraub, Sandra ; Mesulam, Marsel ; Hatanpaa, Kimmo J. ; White, Charles L. ; Strong, Michael J. ; Beach, Thomas G. ; Wszolek, Zbigniew K. ; Lippa, Carol ; Caselli, Richard ; Petrucelli, Leonard ; Josephs, Keith A. ; Parisi, Joseph E. ; Knopman, David S. ; Petersen, Ronald C. ; Mackenzie, Ian R. ; Seeley, William W. ; Grinberg, Lea T. ; Miller, Bruce L. ; Boylan, Kevin B. ; Graff-Radford, Neill R. ; Boeve, Bradley F. ; Dickson, Dennis W. ; Rademakers, Rosa. / TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. In: Acta Neuropathologica. 2014 ; Vol. 127, No. 3. pp. 397-406.
@article{ddae9154e826409298cc66743828da76,
title = "TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia",
abstract = "Variants in transmembrane protein 106 B (TMEM106B) modify the disease penetrance of frontotemporal dementia (FTD) in carriers of progranulin (GRN) mutations. We investigated whether TMEM106B is also a genetic modifier of disease in carriers of chromosome 9 open reading frame 72 (C9ORF72) expansions. We assessed the genotype of 325 C9ORF72 expansion carriers (cohort 1), 586 FTD patients lacking C9ORF72 expansions [with or without motor neuron disease (MND); cohort 2], and a total of 1,302 controls for TMEM106B variants (rs3173615 and rs1990622) using MassArray iPLEX and Taqman genotyping assays. For our primary analysis, we focused on functional variant rs3173615, and employed a recessive genotypic model. In cohort 1, patients with C9ORF72 expansions showed a significantly reduced frequency of carriers homozygous for the minor allele as compared to controls [11.9 vs. 19.1 {\%}, odds ratio (OR) 0.57, p = 0.014; same direction as carriers of GRN mutations]. The strongest evidence was provided by FTD patients (OR 0.33, p = 0.009) followed by FTD/MND patients (OR 0.38, p = 0.017), whereas no significant difference was observed in MND patients (OR 0.85, p = 0.55). In cohort 2, the frequency of carriers homozygous for the minor allele was not significantly reduced in patients as compared to controls (OR 0.77, p = 0.079); however, a significant reduction was observed when focusing on those patients with frontotemporal lobar degeneration and TAR DNA-binding protein 43 inclusions (FTLD-TDP; OR 0.26, p < 0.001). Our study identifies TMEM106B as the first genetic factor modifying disease presentation in C9ORF72 expansion carriers. Homozygosity for the minor allele protects carriers from developing FTD, but not from developing MND; similar effects are seen in FTLD-TDP patients with yet unknown genetic causes. These new findings show that the protective effects of TMEM106B are not confined to carriers of GRN mutations and might be relevant for prognostic testing, and as a promising therapeutic target for the entire spectrum of FTLD-TDP.",
keywords = "Amyotrophic lateral sclerosis, C9ORF72, Disease modifier, Frontotemporal dementia, Motor neuron disease, TMEM106B",
author = "{Van Blitterswijk}, Marka and Bianca Mullen and Nicholson, {Alexandra M.} and Bieniek, {Kevin F.} and Heckman, {Michael G.} and Baker, {Matthew C.} and Mariely Dejesus-Hernandez and Finch, {Nicole A.} and Brown, {Patricia H.} and Murray, {Melissa E.} and Hsiung, {Ging Yuek R} and Heather Stewart and Karydas, {Anna M.} and Elizabeth Finger and Andrew Kertesz and Bigio, {Eileen H.} and Sandra Weintraub and Marsel Mesulam and Hatanpaa, {Kimmo J.} and White, {Charles L.} and Strong, {Michael J.} and Beach, {Thomas G.} and Wszolek, {Zbigniew K.} and Carol Lippa and Richard Caselli and Leonard Petrucelli and Josephs, {Keith A.} and Parisi, {Joseph E.} and Knopman, {David S.} and Petersen, {Ronald C.} and Mackenzie, {Ian R.} and Seeley, {William W.} and Grinberg, {Lea T.} and Miller, {Bruce L.} and Boylan, {Kevin B.} and Graff-Radford, {Neill R.} and Boeve, {Bradley F.} and Dickson, {Dennis W.} and Rosa Rademakers",
year = "2014",
month = "3",
doi = "10.1007/s00401-013-1240-4",
language = "English (US)",
volume = "127",
pages = "397--406",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia

AU - Van Blitterswijk, Marka

AU - Mullen, Bianca

AU - Nicholson, Alexandra M.

AU - Bieniek, Kevin F.

AU - Heckman, Michael G.

AU - Baker, Matthew C.

AU - Dejesus-Hernandez, Mariely

AU - Finch, Nicole A.

AU - Brown, Patricia H.

AU - Murray, Melissa E.

AU - Hsiung, Ging Yuek R

AU - Stewart, Heather

AU - Karydas, Anna M.

AU - Finger, Elizabeth

AU - Kertesz, Andrew

AU - Bigio, Eileen H.

AU - Weintraub, Sandra

AU - Mesulam, Marsel

AU - Hatanpaa, Kimmo J.

AU - White, Charles L.

AU - Strong, Michael J.

AU - Beach, Thomas G.

AU - Wszolek, Zbigniew K.

AU - Lippa, Carol

AU - Caselli, Richard

AU - Petrucelli, Leonard

AU - Josephs, Keith A.

AU - Parisi, Joseph E.

AU - Knopman, David S.

AU - Petersen, Ronald C.

AU - Mackenzie, Ian R.

AU - Seeley, William W.

AU - Grinberg, Lea T.

AU - Miller, Bruce L.

AU - Boylan, Kevin B.

AU - Graff-Radford, Neill R.

AU - Boeve, Bradley F.

AU - Dickson, Dennis W.

AU - Rademakers, Rosa

PY - 2014/3

Y1 - 2014/3

N2 - Variants in transmembrane protein 106 B (TMEM106B) modify the disease penetrance of frontotemporal dementia (FTD) in carriers of progranulin (GRN) mutations. We investigated whether TMEM106B is also a genetic modifier of disease in carriers of chromosome 9 open reading frame 72 (C9ORF72) expansions. We assessed the genotype of 325 C9ORF72 expansion carriers (cohort 1), 586 FTD patients lacking C9ORF72 expansions [with or without motor neuron disease (MND); cohort 2], and a total of 1,302 controls for TMEM106B variants (rs3173615 and rs1990622) using MassArray iPLEX and Taqman genotyping assays. For our primary analysis, we focused on functional variant rs3173615, and employed a recessive genotypic model. In cohort 1, patients with C9ORF72 expansions showed a significantly reduced frequency of carriers homozygous for the minor allele as compared to controls [11.9 vs. 19.1 %, odds ratio (OR) 0.57, p = 0.014; same direction as carriers of GRN mutations]. The strongest evidence was provided by FTD patients (OR 0.33, p = 0.009) followed by FTD/MND patients (OR 0.38, p = 0.017), whereas no significant difference was observed in MND patients (OR 0.85, p = 0.55). In cohort 2, the frequency of carriers homozygous for the minor allele was not significantly reduced in patients as compared to controls (OR 0.77, p = 0.079); however, a significant reduction was observed when focusing on those patients with frontotemporal lobar degeneration and TAR DNA-binding protein 43 inclusions (FTLD-TDP; OR 0.26, p < 0.001). Our study identifies TMEM106B as the first genetic factor modifying disease presentation in C9ORF72 expansion carriers. Homozygosity for the minor allele protects carriers from developing FTD, but not from developing MND; similar effects are seen in FTLD-TDP patients with yet unknown genetic causes. These new findings show that the protective effects of TMEM106B are not confined to carriers of GRN mutations and might be relevant for prognostic testing, and as a promising therapeutic target for the entire spectrum of FTLD-TDP.

AB - Variants in transmembrane protein 106 B (TMEM106B) modify the disease penetrance of frontotemporal dementia (FTD) in carriers of progranulin (GRN) mutations. We investigated whether TMEM106B is also a genetic modifier of disease in carriers of chromosome 9 open reading frame 72 (C9ORF72) expansions. We assessed the genotype of 325 C9ORF72 expansion carriers (cohort 1), 586 FTD patients lacking C9ORF72 expansions [with or without motor neuron disease (MND); cohort 2], and a total of 1,302 controls for TMEM106B variants (rs3173615 and rs1990622) using MassArray iPLEX and Taqman genotyping assays. For our primary analysis, we focused on functional variant rs3173615, and employed a recessive genotypic model. In cohort 1, patients with C9ORF72 expansions showed a significantly reduced frequency of carriers homozygous for the minor allele as compared to controls [11.9 vs. 19.1 %, odds ratio (OR) 0.57, p = 0.014; same direction as carriers of GRN mutations]. The strongest evidence was provided by FTD patients (OR 0.33, p = 0.009) followed by FTD/MND patients (OR 0.38, p = 0.017), whereas no significant difference was observed in MND patients (OR 0.85, p = 0.55). In cohort 2, the frequency of carriers homozygous for the minor allele was not significantly reduced in patients as compared to controls (OR 0.77, p = 0.079); however, a significant reduction was observed when focusing on those patients with frontotemporal lobar degeneration and TAR DNA-binding protein 43 inclusions (FTLD-TDP; OR 0.26, p < 0.001). Our study identifies TMEM106B as the first genetic factor modifying disease presentation in C9ORF72 expansion carriers. Homozygosity for the minor allele protects carriers from developing FTD, but not from developing MND; similar effects are seen in FTLD-TDP patients with yet unknown genetic causes. These new findings show that the protective effects of TMEM106B are not confined to carriers of GRN mutations and might be relevant for prognostic testing, and as a promising therapeutic target for the entire spectrum of FTLD-TDP.

KW - Amyotrophic lateral sclerosis

KW - C9ORF72

KW - Disease modifier

KW - Frontotemporal dementia

KW - Motor neuron disease

KW - TMEM106B

UR - http://www.scopus.com/inward/record.url?scp=84896718565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896718565&partnerID=8YFLogxK

U2 - 10.1007/s00401-013-1240-4

DO - 10.1007/s00401-013-1240-4

M3 - Article

VL - 127

SP - 397

EP - 406

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 3

ER -